These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 29198)

  • 41. The effect of cholecystokinin octapeptide on rat striatal 3H spiperone binding.
    O'Shaughnessy C; Poat JA; Turnbull MJ
    Biochem Pharmacol; 1985 Aug; 34(15):2675-7. PubMed ID: 4015708
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Inhibition of in vivo 3H-spiperone binding by the proposed antipsychotic Des-Tyr1-gamma-endorphin.
    Pedigo NW; Schallert T; Overstreet DH; Ling NC; Ragan P; Reisine TD; Yamamura HI
    Eur J Pharmacol; 1979 Dec; 60(4):359-64. PubMed ID: 43261
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [3H]Spiperone binding sites in brain: autoradiographic localization of multiple receptors.
    Palacios JM; Niehoff DL; Kuhar MJ
    Brain Res; 1981 Jun; 213(2):277-89. PubMed ID: 7248759
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The in vivo and in vitro occupation of [3H]-spiperone binding sites in the frontal cortex and striatum by putative 5-hydroxytryptamine antagonists.
    Clements-Jewery S; Robson PA
    Neuropharmacology; 1980 Jul; 19(7):657-61. PubMed ID: 7402453
    [No Abstract]   [Full Text] [Related]  

  • 45. Identification of stereospecific [3H]spiroperidol binding sites in mammalian lymphocytes.
    Le Fur G; Phan T; Uzan A
    Life Sci; 1980 Apr; 26(14):1139-48. PubMed ID: 7392792
    [No Abstract]   [Full Text] [Related]  

  • 46. Ovine prolactin administration modifies [3H]spiperone binding to striatal membranes of rabbits.
    Eva C; Blengio M; Ferretti C; Muccioli G; Portaleone P
    Brain Res; 1982 Nov; 251(2):388-90. PubMed ID: 7139336
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dopamine receptors in bovine retina : characterization of the 3H-spiroperidol binding and its use for screening dopamine receptor affinity of drugs.
    Magistretti PJ; Schorderet M
    Life Sci; 1979 Nov; 25(19):1675-86. PubMed ID: 41997
    [No Abstract]   [Full Text] [Related]  

  • 48. Increase in in vivo (3H) spiperone binding in the rat hippocampal formation and striatum after repeated treatment with haloperidol.
    Bischoff S
    Experientia; 1981; 37(9):1008-9. PubMed ID: 7297644
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of chronic sulpiride on striatal spiperone binding.
    Bannet J; Gillis S; Ebstein RP; Belmaker RH
    Int Pharmacopsychiatry; 1980; 15(6):334-7. PubMed ID: 7298264
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Discrimination of multiple [3H]5-hydroxytryptamine binding sites by the neuroleptic spiperone in rat brain.
    Pedigo NW; Yamamura HI; Nelson DL
    J Neurochem; 1981 Jan; 36(1):220-6. PubMed ID: 7463047
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Specific binding of [11C]spiroperidol in rat brain in vivo.
    Arnett CD; Fowler JS; Wolf AP; MacGregor RR
    J Neurochem; 1983 Feb; 40(2):455-9. PubMed ID: 6185638
    [TBL] [Abstract][Full Text] [Related]  

  • 52. 125I-Spiperone: a novel ligand for D2 dopamine receptors.
    Gundlach AL; Largent BL; Snyder SH
    Life Sci; 1984 Nov; 35(19):1981-8. PubMed ID: 6149442
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Quantitative assessment of heterogeneous 3H-spiperone binding to rat neostriatum and frontal cortex.
    Howlett DR; Nahorski SR
    Life Sci; 1980 Feb; 26(7):511-7. PubMed ID: 7366332
    [No Abstract]   [Full Text] [Related]  

  • 54. Functional distinction between DA-stimulated adenylate cyclase and 3H-spiperone binding sites in rat striatum.
    Waddington JL; Cross AJ; Longden A; Owen F; Poulter M
    Eur J Pharmacol; 1979 Oct; 58(3):341-2. PubMed ID: 510367
    [No Abstract]   [Full Text] [Related]  

  • 55. Nigrostriatal lesions enhance striatal 3H-apomorphine and 3H-spiroperidol binding.
    Creese I; Snyder SH
    Eur J Pharmacol; 1979 Jun; 56(3):277-81. PubMed ID: 38973
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Distinctions between ligand-binding sites for [3H]dopamine and D2 dopaminergic receptors characterized with [3H]spiroperidol.
    Hancock AA; Marsh CL
    Mol Pharmacol; 1984 Nov; 26(3):439-51. PubMed ID: 6238230
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Selective and stereospecific interactions of R-SK & F 38393 with [3H]piflutixol but not [3H]spiperone binding to striatal D1 and D2 dopamine receptors: comparisons with SCH 23390.
    O'Boyle KM; Waddington JL
    Eur J Pharmacol; 1984 Mar; 98(3-4):433-6. PubMed ID: 6144559
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A partially rigid butyrophenone analog with extended conformation.
    Chan CC; Farmer PS
    Pharmazie; 1986 Dec; 41(12):835-6. PubMed ID: 2883672
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Modification of morphine-induced changes in striatal (3H)-spiroperidol binding and stereotype-behavior by cyclo(Leu-Gly).
    Ritzmann RF; Lee JM; Fields JZ
    Life Sci; 1982 May; 30(18):1573-80. PubMed ID: 7200563
    [No Abstract]   [Full Text] [Related]  

  • 60. Effect of cyclo(leucyl-glycine) on [3H]spiroperidol binding in the corpus striatum and hypothalamus of spontaneously hypertensive rats.
    Bhargava HN
    Eur J Pharmacol; 1984 Apr; 100(1):109-12. PubMed ID: 6723774
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.